Primary SARS-CoV-2 variant of concern infections elicit broad antibody Fc-mediated effector functions and memory B cell responses

被引:2
|
作者
van der Straten, Karlijn [1 ,2 ]
Guerra, Denise [1 ,2 ]
Kerster, Gius [1 ,2 ]
Claireaux, Mathieu [1 ,2 ]
Grobben, Marloes [1 ,2 ]
Schriek, Angela I. [1 ,2 ]
Boyd, Anders [3 ,4 ]
van Rijswijk, Jacqueline [1 ,2 ]
Tejjani, Khadija [1 ,2 ]
Eggink, Dirk [1 ,2 ,5 ]
Beaumont, Tim [1 ,2 ]
de Taeye, Steven W. [1 ,2 ]
de Bree, Godelieve J. [2 ,6 ]
Sanders, Rogier W. [1 ,2 ,7 ]
van Gils, Marit J. [1 ,2 ]
机构
[1] locat Acad Med Ctr, Dept Med Microbiol & Infect Prevent, Lab Expt Virol, Amsterdam UMC, Amsterdam, Netherlands
[2] Amsterdam Inst Immunol & Infect Dis, Amsterdam, Netherlands
[3] Publ Hlth Serv Amsterdam, Dept Infect Dis, Amsterdam, Netherlands
[4] Stichting HIV monitoring, Amsterdam, Netherlands
[5] Natl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis Control, Bilthoven, Netherlands
[6] Amsterdam UMC, Locat Acad Med Ctr, Dept Anaesthesiol, Amsterdam, Netherlands
[7] Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY USA
关键词
VACCINE; OMICRON; IMMUNITY; SPIKE;
D O I
10.1371/journal.ppat.1012453
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by human sera is a strong correlate of protection against symptomatic and severe Coronavirus Disease 2019 (COVID-19). The emergence of antigenically distinct SARS-CoV-2 variants of concern (VOCs) and the relatively rapid waning of serum antibody titers, however, raises questions about the sustainability of serum protection. In addition to serum neutralization, other antibody functionalities and the memory B cell (MBC) response are suggested to help maintaining this protection. In this study, we investigate the breadth of spike (S) protein-specific serum antibodies that mediate effector functions by interacting with Fc-gamma receptor IIa (Fc gamma RIIa) and Fc gamma RIIIa, and of the receptor binding domain (RBD)-specific MBCs, following a primary SARS-CoV-2 infection with the D614G, Alpha, Beta, Gamma, Delta, Omicron BA.1 or BA.2 variant. Irrespectively of the variant causing the infection, the breadth of S protein-specific serum antibodies that interact with Fc gamma RIIa and Fc gamma RIIIa and the RBD-specific MBC responses exceeded the breadth of serum neutralization, although the Alpha-induced B cell response seemed more strain-specific. Between VOC groups, both quantitative and qualitative differences in the immune responses were observed, suggesting differences in immunogenicity. Overall, this study contributes to the understanding of protective humoral and B cell responses in the light of emerging antigenically distinct VOCs, and highlights the need to study the immune system beyond serum neutralization to gain a better understanding of the protection against emerging variants. The SARS-CoV-2 virus, first identified in 2019, swiftly led to a global pandemic. Crucial for the protection against re-infections are sufficient levels of neutralizing antibodies in the blood. However, SARS-CoV-2 have evolved into antigenically distinct variants of concern (VOC) that escape protection by these neutralizing antibodies. In addition, the relatively rapid waning of serum antibody titers raises questions about the sustainability of protection. In this study, we investigated the ability of antibodies and memory B cells to recognize the emerging variants after primary SARS-CoV-2 infection with different variants of concern. Compared with neutralizing antibodies, antibodies that can mediate Fc-mediated effector functions as well as memory B cells were, in general, more cross-reactive to other variants, irrespectively of the variant causing the infection. However, we found variations in the level of immune responses depending on the infecting variant, indicating differences in the immunogenicity of SARS-CoV-2 VOC. These results highlight the need to study the immune system beyond serum neutralization to gain a better understanding of the protection against emerging variants.
引用
收藏
页数:27
相关论文
共 50 条
  • [41] Memory B cell responses to Omicron subvariants after SARS-CoV-2 mRNA breakthrough infection in humans
    Wang, Zijun
    Zhou, Pengcheng
    Muecksch, Frauke
    Cho, Alice
    Ben Tanfous, Tarek
    Canis, Marie
    Witte, Leander
    Johnson, Brianna
    Raspe, Raphael
    Schmidt, Fabian
    Bednarski, Eva
    Da Silva, Justin
    Ramos, Victor
    Zong, Shuai
    Turroja, Martina
    Millard, Katrina G.
    Yao, Kai-Hui
    Shimeliovich, Irina
    Dizon, Juan
    Kaczynska, Anna
    Jankovic, Mila
    Gazumyan, Anna
    Oliveira, Thiago Y.
    Caskey, Marina
    Gaebler, Christian
    Bieniasz, Paul D.
    Hatziioannou, Theodora
    Nussenzweig, Michel C.
    JOURNAL OF EXPERIMENTAL MEDICINE, 2022, 219 (12):
  • [42] Vaccines against the original strain of SARS-CoV-2 provide T cell memory to the B.1.1.529 variant
    Doernte, Charlyn
    Traska, Verena
    Jansen, Nicole
    Kostyra, Julia
    Baurmann, Herrad
    Lauer, Gereon
    Huang, Yi-Ju
    Kramer, Sven
    Brauns, Olaf
    Winkels, Holger
    Schmitz, Juergen
    Dose, Christian
    Richter, Anne
    Schuster, Marc
    COMMUNICATIONS MEDICINE, 2022, 2 (01):
  • [43] Vaccines against the original strain of SARS-CoV-2 provide T cell memory to the B.1.1.529 variant
    Charlyn Dörnte
    Verena Traska
    Nicole Jansen
    Julia Kostyra
    Herrad Baurmann
    Gereon Lauer
    Yi-Ju Huang
    Sven Kramer
    Olaf Brauns
    Holger Winkels
    Jürgen Schmitz
    Christian Dose
    Anne Richter
    Marc Schuster
    Communications Medicine, 2
  • [44] B-cell ELISpot assay to analyze human memory B cell and plasmablast responses specific to SARS-CoV-2 domain
    Rouers, Angeline
    Tay, Matthew Zirui
    Ng, Lisa F. P.
    Renia, Laurent
    STAR PROTOCOLS, 2023, 4 (01):
  • [45] Antibody Fc receptor binding and T cell responses to homologous and heterologous immunization with inactivated or mRNA vaccines against SARS-CoV-2
    Cohen, Carolyn A.
    Leung, Nancy H. L.
    Kaewpreedee, Prathanporn
    Lee, Kelly W. K.
    Jia, Janice Zhirong
    Cheung, Alan W. L.
    Cheng, Samuel M. S.
    Mori, Masashi
    Ip, Dennis K. M.
    Poon, Leo L. M.
    Peiris, J. S. Malik
    Cowling, Benjamin J.
    Valkenburg, Sophie A.
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [46] B Cell Response Induced by SARS-CoV-2 Infection Is Boosted by the BNT162b2 Vaccine in Primary Antibody Deficiencies
    Pulvirenti, Federica
    Fernandez Salinas, Ane
    Milito, Cinzia
    Terreri, Sara
    Piano Mortari, Eva
    Quintarelli, Concetta
    Di Cecca, Stefano
    Lagnese, Gianluca
    Punziano, Alessandra
    Guercio, Marika
    Bonanni, Livia
    Auria, Stefania
    Villani, Francesca
    Albano, Christian
    Locatelli, Franco
    Spadaro, Giuseppe
    Carsetti, Rita
    Quinti, Isabella
    CELLS, 2021, 10 (11)
  • [47] SARS-CoV-2 mRNA vaccination affects antibody and cellular immune responses after B-cell depletion therapies
    Longbrake, Erin
    Asashima, Hiromitsu
    Kim, Dongjoo
    Wang, Elliot
    Lele, Nikhil
    Buitrago, Nicholas
    Lutz, Rachel
    Cruz, Isabella
    Radassi, Khadir
    Ruff, William
    Racke, Michael
    Wilson, Jodell
    Givens, Tara
    Grifoni, Alba
    Weiskopf, Daniela
    Kleinstein, Steven
    Sette, Alessandro
    Montgomery, Ruth
    Shaw, Albert
    Li, Fangyong
    Fan, Rong
    Hafler, David
    Tomayko, Mary
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 481 - 482
  • [48] Interval between prior SARS-CoV-2 infection and booster vaccination impacts magnitude and quality of antibody and B cell responses
    Buckner, Clarisa M.
    Kardava, Lela
    El Merhebi, Omar
    Narpala, Sandeep R.
    Serebryannyy, Leonid
    Lin, Bob C.
    Wang, Wei
    Zhang, Xiaozhen
    Assis, Felipe Lopes de
    Kelly, Sophie E. M.
    Teng, I-Ting
    McCormack, Genevieve E.
    Praiss, Lauren H.
    Seamon, Catherine A.
    Rai, M. Ali
    Kalish, Heather
    Kwong, Peter D.
    Proschan, Michael A.
    McDermott, Adrian B.
    Fauci, Anthony S.
    Chun, Tae-Wook
    Moir, Susan
    CELL, 2022, 185 (23) : 4333 - +
  • [49] Discordant humoral and cell-mediated responses to SARS-CoV-2 vaccination in people with multiple sclerosis on B cell depleting agents
    Gadani, S.
    Reyes-Mantilla, M.
    Jank, L.
    Harris, S.
    Douglas, M.
    Smith, M.
    Calabresi, P.
    Mowry, E.
    Fitzgerald, K.
    Bhargava, P.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 789 - 789
  • [50] Neutralizing Antibody Responses against Five SARS-CoV-2 Variants and T Lymphocyte Change after Vaccine Breakthrough Infections from the SARS-CoV-2 Omicron BA.1 Variant in Tianjin, China: A Prospective Study
    ZHANG Ying
    QU Jiang Wen
    ZHENG Min Na
    DING Ya Xing
    CHEN Wei
    YE Shao Dong
    LI Xiao Yan
    LI Yan Kun
    LIU Ying
    ZHU Di
    JIN Can Rui
    WANG LIN
    YANG Jin Ye
    ZHAI Yu
    WANG Er Qiang
    MENG Xing
    BiomedicalandEnvironmentalSciences, 2023, 36 (07) : 614 - 624